Iovance Biotherapeutics (IOVA) Received its Third Buy in a Row


After Cowen & Co. and Piper Jaffray gave Iovance Biotherapeutics (NASDAQ: IOVA) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics today and set a price target of $32.00. The company’s shares closed last Monday at $23.62, close to its 52-week high of $26.59.

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -7.7% and a 34.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Checkpoint Therapeutics.

Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.50, representing a 37.0% upside. In a report issued on November 5, Chardan Capital also reiterated a Buy rating on the stock with a $30.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.59 and a one-year low of $7.26. Currently, Iovance Biotherapeutics has an average volume of 1.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts